Myassar Zarif, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $352,150 of the $438,124 with a category attached, or 80.4%. 52 manufacturers reported payments, led by Biogen at 32.2% of the total. Reporting peaked in 2019 at $138,842 and has fallen 92.1% since, to $10,965 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 996 payments — averaging $439.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$141K
- Amgen$110K
- Sanofi$35K
- AstraZeneca$33K
- EMD Serono, Inc.$28K
- Genentech USA, Inc.$22K
- plus $69K from 46 others
Across 91 payments — averaging $2211.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$192K
- Roche Products Limited$9K
What the payments were for
- Consulting fees$32,8397%
- Speaking & faculty fees$352,15080%
- Travel & lodging$26,8706%
- Food & beverage$26,1376%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$438,124 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 59 | $649,331 |
| CopaxoneGlatiramer Acetate | 67 | $481,599 |
| VumerityDiroximel Fumarate | 37 | $479,408 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 23 | $329,015 |
| TysabriNatalizumab | 35 | $308,115 |
| GilenyaFingolimod Hcl | 19 | $236,695 |
| AubagioTeriflunomide | 20 | $175,012 |
| Nurtec OdtRimegepant Sulfate | 51 | $80,189 |
| Dalfampridine ErDalfampridine | 73 | $57,813 |
| LyricaPregabalin | 29 | $17,952 |
| Lamictal XrLamotrigine | 12 | $16,996 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $15,728 |
| Gabapentin | 428 | $9,238 |
| BriviactBrivaracetam | 11 | $9,015 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $8,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tysabri | $141,206 | $787,52372 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $16,117 | $481,59967 claims |
| NovartisGilenya | $20,153 | $236,69519 claims |
| SanofiAubagio | $34,573 | $175,01220 claims |
| PfizerNurtec Odt, Lyrica | $151 | $98,14180 claims |
| UCB, Inc.Briviact | $42 | $9,01511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Islip
- Mark GudesblattIslip$209K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.